Investigational drug · Phase 3
Brenetafusp
Also called: IMC-F106C
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Select Advanced Solid Tumors, Advanced Melanoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Brenetafusp"
First trial start
2020
Feb 25, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Brenetafusp", any sponsor or status.
Conditions studied
As listed on its trial records.
- Select Advanced Solid Tumors
- Advanced Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "Brenetafusp" as an intervention, largest first.
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)Pivotal-lookingRecruiting
Immunocore LtdIndustry
NCT06112314 · 680 participants (planned) · Start Jun 5, 2024 · Primary completion Oct 16, 2027
Drug: Brenetafusp; Nivolumab and 1 more · For: Advanced Melanoma
Sites: Tucson, Arizona; La Jolla, California; Los Angeles, California · 211 sites in all
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruiting
Immunocore LtdIndustry
NCT04262466 · 410 participants · Start Feb 25, 2020 · Primary completion Oct 2026
Drug: Brenetafusp; Brenetafusp and pembrolizumab and 5 more · For: Select Advanced Solid Tumors
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 76 sites in all
- Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare CancersNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07686367 · 42 participants (planned) · Start Jan 19, 2027 · Primary completion Nov 30, 2027
Drug: Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C · For: Metastatic Myxoid Liposarcoma; Metastatic Synovial Sarcoma; Unresectable Myxoid Liposarcoma and 1 more
Newest research
PubMed records naming it or its code names, newest first.
- Cytokine release syndrome across three immunotherapy platforms: A real-world patient-level comparison of CAR T-cell, T-cell engager, and immune checkpoint inhibitor therapies.
Wein L, Ertl C, Rejeski K, et al. · Eur J Cancer 2026
- Shared PRAME epitopes are T-cell targets in NUT carcinoma.
Jensen JL, Peterson SK, Sambade MJ, et al. · J Immunother Cancer 2026
- Shared PRAME Epitopes are T-Cell Targets in NUT Carcinoma.
Jensen JL, Peterson SK, Sambade M, et al. · bioRxiv 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.